The Cenrifki from Sanofi S.A. - new EU option for advanced multiple sclerosis

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-23, 20:18. Details in the imprint.

“The Cenrifki from Sanofi S.A.” is printed in small, sharp blue letters on the prototype carton that neurologist Dr. Anna Keller turns over in her hand, the cardboard faintly rough against her fingers. For her patients with secondary progressive multiple sclerosis, this new tablet finally looks like something different on the shelf.

What Cenrifki is meant to do

Cenrifki is Sanofi's new Bruton's tyrosine kinase inhibitor aimed at adults with secondary progressive multiple sclerosis (SPMS) who have not had relapses for at least two years. The European Commission has granted a marketing authorization for this specific group of patients across the EU.

Sanofi positions Cenrifki as a disability-targeting therapy rather than another relapse-prevention drug, which is a notable shift for SPMS without relapses. According to the company, the approval rests on a late-stage clinical trial program that tracked disability progression over time.

Launch, price and first market

Sanofi plans to make Cenrifki commercially available in Germany as the first EU market, with the rollout starting later this year. Other European countries are expected to follow after national reimbursement and pricing negotiations.

An official list price has not yet been disclosed, but analysts expect Cenrifki to land in the typical price corridor for newly approved oral MS therapies. For German patients, neurologists anticipate tight prior-authorization rules given the focused label.

How Cenrifki differs from older MS drugs

Cenrifki targets Bruton's tyrosine kinase, a signaling protein involved in B-cell activity and immune microglia thought to drive chronic inflammation in MS lesions. This mode of action aims at underlying disease biology even when overt relapses have faded.

By contrast, many older MS treatments focus on reducing relapses and MRI lesion activity rather than directly addressing progression in SPMS without relapses. For patients already on the slowly worsening path, that distinction matters in everyday life.

Clinical data in the background

According to Sanofi, the EU green light rests primarily on a late-stage study that assessed disability progression in SPMS, complemented by trials in relapsing MS forms that supplied additional safety and efficacy data. The dataset includes several thousand patients across multiple continents.

Regulators in the United States were more cautious and previously declined an application for the same molecule, then called tolebrutinib, citing an unfavorable benefit-risk profile at the time. That divergence between FDA and EU views is likely to be watched closely by clinicians and investors alike.

What doctors and patients might notice

For neurologists like Dr. Keller, the practical detail is simple: Cenrifki comes as an oral treatment, taken once daily according to Sanofi's description in its communications with regulators. That tablet format is easier to fit into a workday than infusions or frequent injections for many SPMS patients.

Patients, on the other hand, will listen closely to the safety briefing. BTK inhibitors come with their own risk profile, including potential liver enzyme elevations and infection risks, so regular blood tests and monitoring will stay part of the routine. Balancing that with the hope of slowing disability will be the real world trade-off.

Company context and stock angle

For Sanofi, Cenrifki arrives as part of a broader push into immunology and neurology, alongside other BTK inhibitors like Japan-approved Wayrilz for immune thrombocytopenia. The company is clearly betting that this drug class will become a strategic pillar in its mid-term pipeline.

Sanofi S.A. shares (ISIN FR0000120578) trade primarily on Euronext Paris, where investors will be watching how fast Cenrifki wins reimbursement and prescription share in Germany and beyond.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.